J. Scott Garland's Net Worth
$1.8 Million
Who is J. Scott Garland?
J. Scott Garland has an estimated net worth of $1.8 Million. This is based on reported shares across multiple companies, which include Relypsa Inc, EXELIXIS, INC., Day One Biopharmaceuticals, Inc., Karyopharm Therapeutics Inc., Calithera Biosciences, Inc., ALX ONCOLOGY HOLDINGS INC, PORTOLA PHARMACEUTICALS INC, and Olema Pharmaceuticals, Inc..
SEC CIK
J. Scott Garland's CIK is 0001533228
Past Insider Trading and Trends
2016 was J. Scott Garland's most active year for acquiring shares with 5 total transactions. J. Scott Garland's most active month to acquire stocks was the month of May. 2020 was J. Scott Garland's most active year for disposing of shares, totalling 9 transactions. J. Scott Garland's most active month to dispose stocks was the month of June. 2020 saw J. Scott Garland paying a total of $9,806.28 for 441,173 shares, this is the most they've acquired in one year. In 2020 J. Scott Garland cashed out on 1,005,124 shares for a total of $1,577,116.47, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Relypsa Inc No price found
SVP & Chief Commercial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -14.35K |
$32.00 | -$592,384.00 |
0
|
Sep 1
| |||
Form 4
| -4.68% | -705.00 |
$31.89 | -$22,482.45 | 14.35K |
Aug 15
| |||
Form 4
| +9.45% | 1.3K |
$19.96 | -$15,628.68 | 15.05K |
Jun 3
| |||
Form 4
| +83.33% | 6.25K |
—
|
—
| 13.75K |
Nov 6
| |||
Form 4
|
∞
| 7.5K |
—
|
—
| 7.5K |
Aug 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
EXELIXIS, INC. (EXEL) Snapshot price: $20.215
EVP & Chief Commerical Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 20
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Day One Biopharmaceuticals, Inc. (DAWN) Snapshot price: $15.83
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Karyopharm Therapeutics Inc. (KPTI) Snapshot price: $1.68
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 19
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Calithera Biosciences, Inc. (CALA) Snapshot price: $0.03
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 31
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||